Altered placebo and drug labeling changes the outcome of episodic migraine attacks

Science Translational Medicine

Volumn 6, Issue 218, 2014, Pages

  Kam Hansen, Slavenka ^a   Jakubowski, Moshe ^a   Kelley, John M ^a,b,c   Kirsch, Irving ^a,d   Hoaglin, David C ^e   Kaptchuk, Ted J ^a   Burstein, Rami ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ENDICOTT COLLEGE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF PLYMOUTH   (United Kingdom)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; PLACEBO; RIZATRIPTAN;

ANALGESIA; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG LABELING; EPISODIC MIGRAINE; HUMAN; MAJOR CLINICAL STUDY; OPEN STUDY; PLACEBO EFFECT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

DRUG LABELING; ENDPOINT DETERMINATION; HUMANS; MIGRAINE DISORDERS; PAIN MEASUREMENT; PLACEBOS; TREATMENT OUTCOME; TRIAZOLES; TRYPTAMINES;

EID: 84892514261     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006175     Document Type: Article

References (21)

1. D. G. Finniss, T. J. Kaptchuk, F. Miller, F. Benedetti, Biological, clinical, and ethical advances of placebo effects. Lancet 375, 686-695 (2010).
2. J. Metrik, C. W. Kahler, B. Reynolds, J. E. McGeary, P. M. Monti, M. Haney, H. de Wit, D. J. Rohsenow, Balanced placebo design with marijuana: Pharmacological and expectancy effects on impulsivity and risk taking. Psychopharmacology 223, 489-499 (2012).
3. 9- tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164, 61-70 (2002).
4. N. D. Volkow, G. J. Wang, Y. Ma, J. S. Fowler, C. Wong, M. Jayne, F. Telang, J. M. Swanson, Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage 32, 1782-1792 (2006).
5. S. H. Mitchell, C. L. Laurent, H. de Wit, Interaction of expectancy and the pharmacological effects of d-amphetamine: Subjective effects and self-administration. Psychopharmacology 125, 371-378 (1996).
6. J. G. Hull, C. F. Bond Jr., Social and behavioral consequences of alcohol consumption and expectancy: A meta-analysis. Psychol. Bull. 99, 347-360 (1986).
7. Headache Classification Subcommittee of the International Headache Society, The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24 (Suppl. 1), 9-160 (2004).
8. T. J. Kaptchuk, E. Friedlander, J.M. Kelley, M. N. Sanchez, E. Kokkotou, J. P. Singer, M. Kowalczykowski, F. G. Miller, I. Kirsch, A. J. Lembo, Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PLOS One 5, e15591 (2010).
9. J. M. Kelley, T. J. Kaptchuk, C. Cusin, S. Lipkin, M. Fava, Open-label placebo for major depressive disorder: A pilot randomized controlled trial. Psychother. Psychosom. 81, 312-314 (2012).
10. L. A. Schenk, C. Sprenger, S. Geuter, C. Büchel, Expectation requires treatment to boost pain relief: An fMRI study. Pain 10.1016/j.pain.2013.09.024 (2013).
11. I. Kirsch, Response expectancy as a determinant of experience and behavior. Am. Psychol. 40, 1189-1202 (1985).
12. F. Benedetti, A. Pollo, L. Lopiano, M. Lanotte, S. Vighetti, I. Rainero, Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J. Neurosci. 23, 4315-4323 (2003).
13. A. Pollo, M. Amanzio, A. Arslanian, C. Casadio, G. Maggi, F. Benedetti, Response expectancies in placebo analgesia and their clinical relevance. Pain 93, 77-84 (2001).
14. K. B. Jensen, T. J. Kaptchuk, I. Kirsch, J. Raicek, K. M. Lindstrom, C. Berna, R. L. Gollub, M. Ingvar, J. Kong, Nonconscious activation of placebo and nocebo pain responses. Proc. Natl. Acad. Sci. U.S.A. 109, 15959-15964 (2012).
15. M. Amanzio, A. Pollo, G. Maggi, F. Benedetti, Response variability to analgesics: A role for non-specific activation of endogenous opioids. Pain 90, 205-215 (2001).
16. L. Colloca, L. Lopiano, M. Lanotte, F. Benedetti, Overt versus covert treatment for pain, anxiety, and Parkinson 's disease. Lancet Neurol. 3, 679-684 (2004).
17. S. C. Lidstone, M. Schulzer, K. Dinelle, E. Mak, V. Sossi, T. J. Ruth, R. de la Fuente-Fernández, A. G. Phillips, A. J. Stoessl, Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 67, 857-865 (2010).
18. J. F. Bergmann, O. Chassany, J. Gandiol, P.Deblois, J. A. Kanis, J. M. Segrestaa, C. Caulin, R. Dahan, A randomised clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer pain. Clin. Trials Metaanal. 29, 41-47 (1994).
19. R. A. Wise, S. J. Bartlett, E. D. Brown, M. Castro, R. Cohen, J. T. Holbrook, C. G. Irvin, C. S. Rand, M. M. Sockrider, E. A. Sugar; American Lung Association Asthma Clinical Research Centers, Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research Centers. J. Allergy Clin. Immunol. 124, 436-444, 444e1-444e8 (2009).
20. T. J. Kaptchuk, J. Shaw, C. E. Kerr, L. A. Conboy, J. M. Kelley, T. J. Csordas, A. J. Lembo, E. E. Jacobson, "Maybe I made up the whole thing": Placebos and patients' experiences in a randomized controlled trial. Cult. Med. Psychiatry 33, 382-411 (2009).
21. T. J. Kaptchuk, Placebo studies and ritual theory: A comparative analysis of Navajo, acupuncture and biomedical healing. Philos. Trans. R. Soc. Lond. B Biol. Sci. 366, 1849-1858 (2011).